🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Bladder Urothelial Carcinoma

Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663Phase 2, Phase 31 site📍 Shanghai RenJi Hospital · Tests: [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4, [18F]F-RESCA-RT4 Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA NCT07413523NA1 site📍 Rozzano Istituto Clinico Humanitas · Tests: SBRT Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma NCT06364956Phase 1, Phase 28 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbocicl… Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? NCT07037589n/a1 site📍 Uddevalla Vastra Gotaland Region · Tests: investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed) A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial NCT07726602n/a1 site📍 Portland OHSU Knight Cancer Institute · Tests: Non-Interventional Study Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy NCT06170177n/a1 site📍 Milan IRCCS San Raffaele · Tests: Radical Cystectomy Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer NCT05833867Phase 11 site📍 Cleveland Shilpa Gupta, MD · Tests: Sacituzumab govitecan, Adaptive Radiotherapy Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin Bladder Cancer Screening Trial NCT05646485NA1 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Urinalysis Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer NCT07067749Phase 31 site📍 Rome University of Rome Tor Vergata · Tests: multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), C… Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... NCT06161532Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sacituzumab govitecan, Atezolizumab Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma NCT07870577n/a3 sites📍 Munich📍 Munich📍 Munich Comprehensive Cancer Center Munich (CCCM) Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification NCT07888374n/a1 site📍 Shanghai Ruijin Hospital A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer NCT06503614Phase 25 sites📍 San Francisco📍 Tampa📍 New Brunswick John Sfakianos · Tests: Durvalumab, Monalizumab BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy NCT07869836Phase 32 sites📍 Macon📍 Macon SystImmune Inc. · Tests: T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) A Study of Ward Admissions for Haematuria NCT07395037n/a1 site📍 London British Urology Researchers in Surgical Training · Tests: Inpatient work-up and management FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739Phase 182 sites📍 Tucson📍 Duarte📍 Los Angeles Eli Lilly and Company · Tests: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial NCT06764095Phase 41 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Computed Tomography, Cystectomy, Enfortumab Vedotin, Local Therapy Bio Clinical Collection of Urothelial Carcinoma NCT04970472n/a1 site📍 Toulouse University Hospital, Toulouse · Tests: collection of blood, urines, stool and tumor samples Safely Reduce Cystoscopic Evaluations for Hematuria Patients NCT06026189NA1 site📍 Rotterdam Erasmus Medical Center · Tests: urine-first strategy Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) NCT07855926n/a1 site📍 Munich LMU Klinikum · Tests: Perioperative Systemic Therapy Registry Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer NCT05312671Phase 22 sites📍 Washington D.C.📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Atezolizumab, Carboplatin, Cisplatin, Etoposide, Cystectomy A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer NCT05521698Phase 16 sites📍 Tucson📍 Los Angeles📍 Bethesda University of Wisconsin, Madison · Tests: Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladde… InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer NCT05463796n/a1 site📍 Boston Dana-Farber Cancer Institute · Tests: Samples Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer NCT06809140Phase 25 sites📍 Duarte📍 Indianapolis📍 New York Matthew Galsky · Tests: Enfortumab vedotin, Pembrolizumab Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer NCT06310759n/a8 sites📍 Chicago📍 Vancouver📍 Helsinki Tampere University Hospital Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy